MedPath

Attralus, Inc.

Attralus, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2019-01-01
Employees
11
Market Cap
-
Website
http://www.attralus.com

Clinical Trials

4

Active:0
Completed:2

Trial Phases

2 Phases

Phase 1:2
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (50.0%)
Phase 2
2 (50.0%)

A Study of AT-02 in Subjects With Systemic Amyloidosis.

Phase 2
Recruiting
Conditions
Amyloidosis; Systemic
Interventions
First Posted Date
2023-07-18
Last Posted Date
2025-08-24
Lead Sponsor
Attralus, Inc.
Target Recruit Count
120
Registration Number
NCT05951049
Locations
🇺🇸

Kansas City, Kansas City, Kansas, United States

🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

🇺🇸

OHSU (Oregon Health & Science University), Portland, Oregon, United States

and more 1 locations

Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis

Phase 1
Recruiting
Conditions
Amyloidosis; Systemic
Interventions
Other: AT-02 (Placebo)
First Posted Date
2022-08-30
Last Posted Date
2024-04-03
Lead Sponsor
Attralus, Inc.
Target Recruit Count
100
Registration Number
NCT05521022
Locations
🇺🇸

Midwest Heart and Vascular, Overland Park, Kansas, United States

🇺🇸

Johns Hopkins, Baltimore, Maryland, United States

🇺🇸

St. Luke's Hospital of Kansas City, Kansas City, Missouri, United States

and more 8 locations

A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis

Phase 2
Completed
Conditions
Amyloidosis
Interventions
Drug: I124-AT01 only
First Posted Date
2022-02-11
Last Posted Date
2024-07-31
Lead Sponsor
Attralus, Inc.
Target Recruit Count
27
Registration Number
NCT05235269
Locations
🇺🇸

PET/CT Imaging of Berkeley, Berkeley, California, United States

🇺🇸

Northern California PET Imaging Center, Sacramento, California, United States

🇺🇸

PET/CT Imaging of San Jose, San Jose, California, United States

A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis

Phase 1
Completed
Conditions
Amyloidosis; Systemic
Interventions
First Posted Date
2022-01-21
Last Posted Date
2022-09-15
Lead Sponsor
Attralus, Inc.
Target Recruit Count
13
Registration Number
NCT05201911
Locations
🇺🇸

University of Tennessee Medical Center, Knoxville, Tennessee, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.